Performance chart
* S&P Global LargeMidCap Index (50% hedged into NZD)
Fund performance figures are after deductions for charges but before tax. Please note that past performance is not necessarily indicative of future returns. Returns can be positive or negative, and returns over different time periods may vary. No returns are promised or guaranteed.
Fund highlights
April 2026
The International Growth Fund returned +4.0% in April, behind the benchmark index which rose +7.9%.
Amazon (+27%) was the largest contributor. While its core retail business exceeded expectations, strength was driven by Amazon Web Services (AWS), where revenue reaccelerated alongside continued capacity investment to meet strong demand for AI and traditional cloud services. Amazon’s proprietary chips (Trainium and Graviton) support a differentiated full-stack AI offering, from silicon to application layer, with chip-related revenue already at a ~$20 billion run-rate. Margins also impressed, beating expectations across all segments. This was a broader theme across big tech. Alphabet (+34%), Amazon, and Meta (+7%) are demonstrating they can invest heavily in AI while still growing earnings, contrary to prior market concerns.
Healthcare holdings lagged amid a rotation away from quality and defensive sectors into higher-momentum areas. Investor concerns have centred on slowing medical device growth as procedure volumes normalise post-COVID and hospitals tighten capital budgets. However, underlying conditions remain more resilient than sentiment suggests. Procedure volumes are holding up across key categories, and hospital budgets and order books, particularly in robotics, remain solid. Edwards Lifesciences (+4%) and Intuitive Surgical (-1%) both saw revenue growth accelerate. Boston Scientific (-8%) is consolidating after several years of strong performance. While the company delivered 9% revenue growth in Q1, guidance was reduced due to near-term headwinds. Longer term, strong market positions, product innovation, and expected 2027 regulatory approvals, support reacceleration.
Danaher (-6%) reflects a slower recovery in biopharma spending, though biotech funding and pharma R&D trends suggest recovery is a matter of timing. We have reduced healthcare exposure over the past year while maintaining conviction in select high-quality names. Valuations have compressed to near 30-year lows relative to the broader market, creating an attractive opportunity for long-term investors.
Portfolio Team
Our Managed Funds
- Learn more
Conservative Fund
Aims to provide stable returns over the long term by investing mainly in income assets with a modest allocation to growth assets.
- Learn more
Balanced Fund
Aims to provide a balance between stability of returns and growing your investment over the long term by investing in a mix of income and growth assets.
- Learn more
Growth Fund
Aims to grow your investment over the long term by investing mainly in growth assets.
- Learn more
Aggressive Fund
Aims to grow your investment over the long term by investing predominantly in growth assets.
- Learn more
Income Fund
Aims to provide stable returns over the long term by investing in New Zealand and international fixed interest assets.
- Learn more
Property & Infrastructure Fund
Focuses on growth of your investment over the long term by investing in New Zealand and international property and infrastructure assets.
- Learn more
New Zealand Growth Fund
Focuses on growth of your investment over the long term by investing in quality New Zealand companies which can consistently produce increasing earnings.
- Learn more
Australian Growth Fund
Focuses on growth of your investment over the long term by investing in quality Australian companies which can consistently produce increasing earnings.
- Learn more
International Growth Fund
Focuses on growth of your investment over the long term by investing in quality international companies which can consistently produce increasing earnings.